Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Source: Eur Respir J 2002; 20: 52-58 Year: 2002
Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study Source: Eur Respir J 2002; 20: 332-338 Year: 2002
The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006
Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
Haemodynamic testing in primary pulmonary hypertension - effects of nitric oxide, iloprost and oxygen Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016
Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013
Postural change in lung capillary blood volume is less in pulmonary hypertension (PH) compared to healthy controls Source: International Congress 2015 – Lung function: effects on method, machine and disease on the measurement Year: 2015
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009
The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction Source: Eur Respir J 2003; 21: 19-24 Year: 2003
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function Source: Eur Respir J 2001; 17: 934-938 Year: 2001